Workflow
Arbutus Biopharma(ABUS) - 2025 Q2 - Quarterly Results

EXHIBIT 99.1 Arbutus Reports Second Quarter 2025 Financial Results and Provides Corporate Update Q2 total revenue of 10.7MincludespreviouslydeferredrevenuefollowingreacquisitionofGreaterChinarightstoimdusiranDr.RogerSawhneyjoinstheArbutusBoardofDirectorsfollowingresignationofAnujHasijaDr.HarryJanssenjoinstheArbutusScientificAdvisoryBoardStrongfinancialpositionwithcash,cashequivalentsandmarketablesecuritiesof10.7M includes previously-deferred revenue following reacquisition of Greater China rights to imdusiran Dr. Roger Sawhney joins the Arbutus Board of Directors following resignation of Anuj Hasija Dr. Harry Janssen joins the Arbutus Scientific Advisory Board Strong financial position with cash, cash equivalents and marketable securities of 98.1M WARMINSTER, Pa., Aug. 06, 2025 (GLOBE NEWSWIRE ...